Global private equity and venture capital news and research

Posts Tagged ‘Lundbeckfond Ventures’

28 October 2016

Bonesupport nabs $37m from returning PE,VC backers in latest financing round

skeleton-1243818_640 Scandinavian medtech specialist Bonesupport has raised SEK 327m ($37m) in a PE and VC-backed financing round led by Nordic investment firm Tellacq.

8 September 2015

Ysios Capital leads €36.6m Series C for drug developer Sanifit

pills-530372_1280 Spanish early-stage investment firm Ysios Capital has led a €36.6m Series C investment round for clinical-stage biopharma business Laboratoris Sanifit.

9 June 2015

Lundbeckfond Ventures leads $30m Spero Therapeutics Series A

bacteria Lundbeckfond Ventures has led a $30m Series A round for bacterial infection-treating biopharma business Spero Therapeutics.

9 January 2015

Rare disease drug developer Vtesse nets $25m NEA-led Series A

pharma pills drugs treatment New Enterprise Associates has led a $25m Series A financing round for rare disease drug developer Vtesse.

24 July 2014

Flesh-eating bacteria specialist picks up $23m Series E led by SR One

pills-1111307-m SR One has led a $23m financing round for Atox Bio, which develops therapeutics for severe infections.

1 May 2014

France’s Enterome Bioscience inks €10m Series B investment

French healthcare developer Enterome Bioscience has raised €10m in the first tranche of a Series B fund raising.

28 March 2014

Biopharma developer scPharmaceuticals seals $16m Series A VC round

Biopharmaceutical company scPharmaceuticals has closed a $16m Series A venture financing round co-led by life sciences investors 5AM Ventures and Lundbeckfond Ventures.

25 February 2014

Novo Ventures leads $49m Series B for anti-acne business Thesan Pharmaceuticals

skin5_lrg Biotechnology business Thesan Pharmaceuticals, which aims to treat skin disorders including acne and dermatitis, has picked up $49m of Series B financing led by existing backer Novo Ventures.

1 October 2013

Bay City Capital, Lundbeckfond latest venture investors in drug accelerator Cydan

drug pharma bottle Bay City Capital and Lundbeckfond Ventures have brought drug accelerator Cydan’s total funding to $26m by backing a new financing round.

15 April 2013

Lundbeckfond Ventures backs DySIS Medical with £6m

Edinburgh-based medical devices maker DySIS Medical has raised £7.4m from venture capital firm Lundbeckfond Ventures and its existing investors.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016